AHA In Brief: Nitinol Medical Technologies
This article was originally published in The Gray Sheet
Executive Summary
Nitinol Medical Technologies: Firm's CardioSeal septal occluder shows "a clinically successful result" in 96% of 82 patients studied, according to initial results presented at the AHA conference in Orlando by Evan Zahn, MD, Miami Children's Hospital. The study involved use of the CardioSeal to treat isolated secundum atrial septal defects "in patients considered to be candidates for open heart surgery," Nitinol says. Results from a separate study sponsored by Children's Hospital, Boston and reported by Kathy Jenkins, MD showed the device could be "an important alternative to surgery for high-risk patients" with a variety of cardiac defects such as ASD, ventricular septal defects, patent foramen ovale and fenestrated fontan," the company says...